Proactive Investors - Run By Investors For Investors

Amryt Pharma's Lojuxta approved for funding as NHS treatment

David Allmond, chief commercial officer at Amryt Pharma PLC (LON:AMYT) tells Proactive Investors their Lojuxta Homozygous Familial Hypercholesterolaemia (HoFH) treatment is to be made available to NHS patients in England.

HoFH is a rare life-threatening disorder that causes abnormally high levels of low density lipoprotein (LDL) cholesterol.

 
View full AMYT profile View Profile

Amryt Pharma PLC Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use